Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO) which specializes in immediate and modified release oral solids and packaging, has announced the appointment of Mr. Lonnie Barish, MBA as Vice President of Business Development and Marketing.
Adding more than 25 years of pharmaceutical, biotech, and medical device experience to the team, Barish will offer local support to new and existing clients in North America whilst helping to boost the growth of Bora’s North American business.
Bobby Sheng, CEO at Bora Pharmaceuticals commented: “We are truly honored to add Lonnie to our growing team in North America.”
“Lonnie has been a senior leader at some of the most dynamic contract service organizations in our industry. He will contribute significant business development and commercial experience alongside a deep understanding of the needs of our pharmaceutical industry customers.”
“As more customers continue to outsource their most challenging oral solid drug products to us, there is a greater need than ever for our extended release and solvent processing capabilities. Lonnie will help us to meet this demand and ensure we are reaching those pharmaceutical companies that would benefit from our skilled team and services.”
Headquartered in Zhunan, Taiwan, Bora recently confirmed plans to acquire GSK’s Mississauga, Canada facility by the end of 2020. The deal, which will considerably increase Bora’s size, capacity, and capabilities to include semi solids and liquids, will see the company commit to retaining approximately 400 GSK staff and continue to produce GSK products for over 100 markets for a minimum of five years.
Barish, who has held leadership roles at Cytovance Biologics, WellSpring, Nuvisan and AAIPharma, is the first of a number of planned key appointments as the company looks to expand its business development team across the continent.
Barish stated: “I was excited to become a member of the Bora team because of its people, its core values, and its commitment to supporting global business strategy for its customers. Its unique experience and commercial capabilities are hard to come by in our industry.”
“Bora’s outstanding regulatory history with the FDA, MHRA, and TFDA coupled with its technical agility are key differentiators in its service offering. In particular, its expertise in spheronization, bilayer tableting, and handling solvents are invaluable to the oral solids market. It’s great to be part of an ambitious team so committed to supporting its customers in the complex oral solids space.”
Across its two sites in Taiwan, Bora offers a broad range of technologies to its global customer-base from development to manufacturing, packaging, distribution, technical transfer, stability studies, and product life cycle management. For more information visit: https://cdmo.bora-corp.com/
About Bora CDMO
Bora is a leading full-service contract development and manufacturing organization (CDMO) that specializes in immediate release and complex modified release drug product manufacturing and packaging for non-sterile oral solid dosage forms.
Employing over 475 people across its two state-of-the-art facilities in Taiwan, the CDMO has the agility and expertise to take on simple to large scale challenging projects, offering tailored solutions for niche drug product requirements.
Bora is set to acquire GSK’s Mississauga facility later this year. The publicly listed company is supported by several investors and shareholders such as UMC and Taishin Financial Holdings.
